Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin

• DOI: 10.6004/jadpro.2020.11.4.8
• Publication Date: 2020-06-15T14:39:53Z
• Authors: Kirollos S. Hanna...
• Keywords: Brentuximab vedotin

The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, Nectin-4-targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration patients with advanced or metastatic UC following chemotherapy and immunotherapy. Approval of enfortumab vedotin based on findings from EV-201 trial, which demonstrated objective response rates 44%. Patients treated should be monitored specific toxicities, including peripheral neuropathy, rash, hyperglycemia. In this article, clinical implications are reviewed.